Central District Health is urging HIV testing, prevention and education after recording new 2026 cases in Ada, Boise, Elmore ...

Both the DEX-sparing and DEX-free approaches met requirements for noninferiority in comparison with standard DEX therapy. The study’s primary endpoint was the proportion of patients reaching a ...

Incyte Corporation INCY on Monday reported complete Phase 1/2 multidose data for latarcibart (VGA039), showing substantial ...

Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, ...

Acquisition adds VGA039, a novel investigational monoclonal antibody in Phase 3 development for patients with von Willebrand disease (VWD), strengthening Incyte’s late-stage pipeline WILMINGTON, Del.- ...

The speed of science is accelerating to address the most significant health concerns facing the world today. At SCHARP, we recognize the importance of data and analytical rigor to provide the insights ...

As explained above, low memory or disk space can also trigger this error. First, close all running programs to free up some RAM. If this does not fix the problem, try ...

At the end of December 2025, 32.1 million people [28.2 million–33.4 million] people were accessing antiretroviral therapy, up from 7.7 million [6.7–8 million] in 2010. In 2025, 78% [62–90%] of all ...

Participants were surveyed on sociodemographic characteristics, sexual and drug-related behaviors, history of preexposure prophylaxis (PrEP) usage, and PEP uptake. Statistical analysis included ...

remove-circle Internet Archive's in-browser bookreader "theater" requires JavaScript to be enabled. It appears your browser does not have it turned on. Please see ...

Venous thromboembolic disease is a major global cause of morbidity and mortality. An estimated 10 million episodes are diagnosed yearly; over half of these episodes are provoked by hospital ...